Shanghai Fosun Pharmaceutical(600196.SH)'s holding subsidiary Fosun Pharma Alliance has received the acceptance of drug registration application.

Shanghai Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary Fosun Pharma has recently had its drug registration application for the compound drug Ripretinib (project code: SAF-189, registration classification: chemical drug class 1; hereinafter referred to as "the new drug") accepted by the National Medical Products Administration. This new drug is an innovative small molecule chemical drug intended for the treatment of non-small cell lung cancer (ALK+) and non-small cell lung cancer (ROS1+). The indication for this application is for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) positivity.